// App-Quantinova.ai

TPS8578 : CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).

Researchers

Presenter

  • Leora Horn

Principal Investigators

  • Martin Reck

  • Scott N. Gettinger

  • David R. Spigel

  • Scott Joseph Antonia

  • Brent A. Rupnow

  • Anne Pieters

  • Giovanni Selvaggi

  • Justin P. Fairchild

  • Solange Peters

Medical Centers

  • Vanderbilt University Medical Center, Nashville, TN

  • Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany

  • Yale Comprehensive Cancer Center, New Haven, CT

  • Sarah Cannon Research Institute, Nashville, TN

  • Moffitt Cancer Center, Tampa, FL

  • Bristol-Myers Sqiubb, Princeton, NJ

  • University Hospital Vaud, Lausanne, Switzerland

Locations

  • United States

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

  • Brain metastasis

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • amrubicin (IV)

  • Nivolumab

  • Topotecan Hydrochloride

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT02481830

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved